Navigation Links
biolitec AG - Record Profit in FY 2006/07 With a Growth of 191% to Euro 6,7 Million
Date:9/28/2007

Sales of biolitec AG Increase to More Than Euro 39 Million - Aesthetic

Therapies and Ambulant Urology Laser are Growth Drivers - 0.56 Euro

Earnings per Share at June 30, 2007

JENA, Germany, September 28 /PRNewswire-FirstCall/ -- http://www.biolitec.com - biolitec AG, Jena listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409) managed to increase the revenues during the fiscal year ending June, 30 2007 by 34 % to Euro 39.04 million (previous year: Euro 29.1 million). The gross profit amounted to Euro 26.5 million (last fiscal year Euro 19.8 million) and the EBIT increased by 191% to Euro 6.7 million (last fiscal year Euro 2.3 million). The operating profit increased by 183 % from Euro 2.4 million to Euro 6.9 million.

Due to the strong sales increase especially with aesthetic treatment methods (ELVeS(TM) etc.) as well as for the BPH treatment and in the disposable business the net income increased to Euro 5.6 million (last fiscal year Euro 2.1 million). Continuous high R&D investments (Euro 5.5 million, 14% of sales) are necessary to ensure the groups long term growth and profitability.

Cash also benefited from the positive results and order situation with an increase to Euro 4.3 million in fiscal year 2006/2007; as the company is nearly free of debt a sound basis for further growth financing is given.

The strongest increase with 78 % respectively 17 % were achieved in our traditional fields' lasers and fibres/probes. The significant contribution of biolitec's turnover once again was achieved in Europe and North America. Due to the strong growth in the USA the North American share of overall sales increased to 48% (last year 41 %).

"biolitec AG expects for the current fiscal year further dynamic growth as well as an improved EBIT. The basis for this accelerated growth lies in the during the expired fiscal year achieved growth of sales of disposables especially from the field of aesthetics as well as the increase of installed equipment base of the ELVeS(TM) and urology lasers. Future growth is also expected to be generated with aesthetics as well as in urology", explains Dr. Wolfgang Neuberger, CEO of biolitec AG. Per June 30, 2007 earnings per share amounts to 0.56 Euro.

The field of urology shows impressively biolitec's innovative power. For the first time, patients suffering from benign prostate hyperplasia can be treated in office with biolitec's urology laser LIFE (Laser Induced Flow Enhancement). For the therapy of prostate enlargement biolitec's BPH treatment method LIFE avoids, in contrast to standard surgery, a stay in hospital for several days. The method guarantees a minimal convalescence and reduces the risks of incontinence and impotence. The laser is the only possibility to treat benign prostate hyperplasia in office without extensive anaesthesia.

First LIFE Laser Centers have already been established in Germany, more of them are going to be established, mostly in metropolitan areas. The therapy has already been used successfully in the USA since the beginning of this year.

About biolitec

biolitec is the only supplier for photodynamic therapy worldwide that offers all relevant core competencies - photosensitizers, lasers and optical fibers. Besides minimal invasive laser treatments and the oncology business biolitec has successfully developed competencies in the field of aesthetics. biolitec is listed in the Prime Standard under ISIN DE0005213409. For more informations: http://www.biolitec.com .

Press contact

Jörn Gleisner

Phone : +49-(0)-69/959083-20

Fax : +49-(0)-69/959083-99

E-mail: j.gleisner@financial-relations.de


'/>"/>
SOURCE biolitec AG
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
2. Record growth of Soya-based dairy alternatives in Europe
3. Gujarat Records Fall In AIDS Cases
4. Record Number of Countries Contributed to UNFPA in 2005
5. Indonesia Records Another Bird Flu Death
6. British Columbia Has The Best Health Record
7. Government Medical Records Find Their Way to the Auctions House
8. Number of Allergic Anaphylaxis Episodes Are Far More Than Those Recorded
9. Apprehension looms large over patient record system
10. Manic Ecstasy: Man gets Into a Frenzy after a Record Consumption of 40,000 ecstasy tablets
11. Decline of Suicide Rates to a Record Low, Holds Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for Garden Media ... All through the year, Garden Media aims to provide material helpful to clients’ goals ... pitching client’s key messages to gain coveted media placements, Garden Media wows ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet ... a conversation on the current obstacles facing infection prevention and offer strategies for ... caused by these infections. , The print component of “Fighting Infection” is ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, ... Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare would ... estimates a reduction in employer-based coverage due to the GOP reform, which is not ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017 Summary ... disease pipeline guide Primary Hyperoxaluria - Pipeline Review, ... Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline ... characterized by recurrent kidney and bladder stones. It ... oxalate. Symptoms include blood in the urine, pain ...
(Date:3/23/2017)... and VANCOUVER, British Columbia ... SPHS ) (the "Company" or "Sophiris"), a ... treatment of urological diseases, today announced that data from ... the drug as a focal treatment for localized prostate ... 26, 2017 at the 32 nd Annual European ...
(Date:3/23/2017)...   Icertis , the leading provider of ... today announced an upgrade to the Icertis Clinical ... clinical trials contract management. Built on the ... speeds up clinical trial contracting while improving collaboration ... "The pharmaceutical industry is under intense ...
Breaking Medicine Technology: